We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current INBX market cap is 198.75M. The company's latest EPS is USD -16.6733 and P/E is -0.82.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 17k | 30k | 119k | 1.63M | 0 |
| Operating Income | -43.77M | -41.34M | -45.83M | -88.29M | -73.83M |
| Net Income | -48.92M | -47.05M | -51.79M | -93.6M | -78.71M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 13.21M | 12.89M | 7.23M | 2.19M | 1.8M |
| Operating Income | -43.71M | -67.44M | -76.56M | -129.12M | -219.22M |
| Net Income | -51.4M | -76.12M | -81.77M | -145.23M | -241.36M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 253.72M | 213.17M | 372.73M | 307.89M | 288.58M |
| Total Liabilities | 238.58M | 237.98M | 243.14M | 264.39M | 277.01M |
| Total Equity | 15.13M | -24.81M | 129.6M | 43.5M | 11.57M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 26.49M | 143.74M | 150.45M | 290.88M | 307.89M |
| Total Liabilities | 60.55M | 68.27M | 98.07M | 232.82M | 264.39M |
| Total Equity | -93.57M | 75.47M | 52.38M | 58.06M | 43.5M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -39.94M | -82.24M | -136.49M | -193.31M | -63.05M |
| Investing | -23k | -340k | -1.15M | -4.59M | -1.12M |
| Financing | 356k | 1.21M | 201.1M | 201.96M | 38.73M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -32.08M | -47.97M | -80.32M | -115.3M | -193.31M |
| Investing | -1.81M | -1.36M | -809k | -686k | -4.59M |
| Financing | 43.33M | 166.46M | 83.77M | 258.55M | 201.96M |
| Market Cap | 198.75M |
| Price to Earnings Ratio | -0.82 |
| Price to Sales Ratio | 110.46 |
| Price to Cash Ratio | 0.72 |
| Price to Book Ratio | 4.57 |
| Dividend Yield | - |
| Shares Outstanding | 14.48M |
| Average Volume (1 week) | 71.92k |
| Average Volume (1 Month) | 161.76k |
| 52 Week Change | -41.40% |
| 52 Week High | 39.79 |
| 52 Week Low | 12.61 |
| Spread (Intraday) | 1.6 (11.07%) |
| Company Name | Inhibrx Biosciences Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.inhibrx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
